Stock & Company Details
Benitec Biopharma Inc $BNTC
Price:
46,691,331
34M
$460M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-4.04
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
BNTC technical indicators
Latest Benitec Biopharma Inc (BNTC) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
56.02 11.4%
MACD:
0.43 2.6%
SMA 50:
$11.81 0.2%
SMA 200:
$12.53 0.1%
EMA 20:
$12.15 0.5%
Bollinger Bands:
13.82 / 9.71
Stochastic:
67.51 3.8%
ADX 14:
24.26 4.8%
ATR 14:
0.84 0.1%
CCI 20:
86.17 22.5%
OBV:
39.41M 0.3%
ROC 12:
13.51% 35.9%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Finance Bot
Ask your questions
Start by typing a question below.
